Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. - Wikidata - wikimedia - TriplyDB

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.

http://www.wikidata.org/entity/Q45099758

about

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling Pathways to tamoxifen resistance.Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.Targeting PTEN-defined breast cancers with a one-two punch.Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Partial PTEN deletion is linked to poor prognosis in breast cancer Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Mechanisms of endocrine resistance in breast cancer.Effects of indomethacin on expression of PTEN tumour suppressor in human cancers PTEN mutation, methylation and expression in breast cancer patients.PTEN in brain tumors.mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss.Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells.Status of PI3K inhibition and biomarker development in cancer therapeutics.Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway.Intrinsic resistance to chemotherapy in breast cancer.Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.Everolimus: targeted therapy on the horizon for the treatment of breast cancer.PI3K in cancer-stroma interactions: bad in seed and ugly in soil.The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.The PI3K Pathway: Background and Treatment Approaches.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.

P2860

Q24813788-047CA855-82A3-4B77-ABFF-F457482CCAA8 Q26862550-7336A613-A7CA-487F-8903-944F43A3A9F6 Q28475546-A39A29A6-ACC1-4588-B682-3FF8A3B00484 Q30441001-5E0DF87C-C8D6-4DEF-8B23-AED675D25885 Q31132241-4B79EC74-2FE5-4ECB-A064-DAFE1D4AEC15 Q33610437-23B962C8-B41F-49B1-A875-79020C879C59 Q34147910-06A5B4F0-BDA5-484B-818B-480B79E78CB1 Q34514602-314CC979-61C4-4E28-A6E9-9951FC58623C Q34857146-03DF0D7F-EFC4-4CA2-AC4F-33EAC54A3D3D Q35000243-A0E56AFB-1103-4FE1-88BE-C9EC36CC8CD5 Q35223770-BD235BC1-92BF-40FA-BD6F-AC6B24E6ED0B Q35312683-A0C86C91-8C54-4314-8E37-93E206B240AC Q35799611-A1EFD3EF-6023-461A-AE50-A34CFB4870CE Q35861503-3CAEBF8A-7F6C-4CED-B414-15D49655C315 Q35870069-1D86EDB2-33E7-401B-A6E9-15D47A307E66 Q36245376-354081B0-BDBF-43BA-9C39-A362C46D2A01 Q36312142-24542465-775D-4897-B9BF-F8B674E0E63D Q36458731-EB3103DA-B8EB-4802-8791-4FD0FDFEA573 Q36547566-26B2B730-E528-46BD-B4C3-53BF3E66772D Q36851417-2556F9C2-7FC5-4B6A-AF65-9C024ADC0C8B Q36943601-CA43C957-6D86-4F23-B96F-8A39EB44F0E4 Q37092758-1701F979-1F36-4D79-BAC4-71B34BB04B35 Q37139779-A1B5B8FF-33AD-4CB4-88CA-8E55C1417775 Q37156750-E6E487DA-4968-4B3A-A7FD-9C6D2C270AB6 Q37255106-FDC5CE93-3DF7-487F-9E16-15A8B1632CB4 Q37346786-1C31C5BC-CA6F-48D4-A897-0F5E0F636690 Q37351516-60C16E02-CD4F-4397-923D-C26058CA0416 Q37588308-CF75983A-0405-4212-9DFB-AFDED78A7C70 Q37588340-D46E5383-CC4D-421F-B3A2-FB5727292DD2 Q37601913-B4B3E886-E2F9-4AB2-A7F1-78DED60E326B Q37813694-5153E55F-FB8F-4A9A-9EF7-9FEEA418FD1D Q37962586-AACEB462-FF50-42FD-9B19-0506FBE65494 Q37998418-1BD574D4-0EFA-4A23-B690-D4340C3CA8FE Q38124762-421D38F3-865C-4FA0-BC6C-EDF7384F95C2 Q38926422-DDE01046-A127-459D-A31E-6F0FF2807C07 Q39147158-7749A3BF-2EB7-45F3-AAB1-9F0BE5430950 Q39520887-E74EAD24-9B19-4679-BEFE-CEDE59D79B2E Q40095128-9E6E6057-7190-465F-8B75-D63090CC5F89 Q42508996-7CCE76CC-BC20-49E3-B438-A3B82EDAD994 Q49912442-F8855EC2-592E-473D-9E81-4B79091EEC79

P2860

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.

http://www.wikidata.org/entity/Q45099758

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@en

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@nl

type

label

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@en

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@nl

prefLabel

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@en

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@nl

P1433

Q45099758-90068780-DFAB-4D96-8BB9-B995CE378AF2

P1476

Q45099758-103F4D9E-6611-4BAF-AF93-2DF3236E2CEA

P2093

Q45099758-0BB7676F-1392-4026-989C-4FC8F22E127C

Q45099758-65AA423A-D602-4150-9851-869211004B0E

Q45099758-90121A0C-DD38-43C3-BD9B-94EA2541A084

Q45099758-C05C5DD4-A341-4181-A7C0-D469584E428B

Q45099758-C10DB15A-B55A-47AC-AEF6-9F553CFCFCBB

Q45099758-CD20D25A-A3F5-4D4A-9913-46A60DE60B19

P2860

Q45099758-000E48A4-F497-445F-A329-181D323DA1AA

Q45099758-07822AE4-321C-4E08-9C0B-B312650B344F

Q45099758-07FF659A-66D4-45FC-AFC4-082CE34C0D5C

Q45099758-0CFD9600-804B-4546-8A09-0380A369D9A5

Q45099758-2978F8AC-288C-4788-B407-1F1C17CAF867

Q45099758-2A6E274E-B73C-4814-BEE6-88FF6FCC71DF

Q45099758-3384233C-8753-4676-B76A-81D40EC07C29

Q45099758-3B8097CD-410F-4F1A-BB8A-6DB7EA100B8E

Q45099758-43CFD2BB-EA5A-4ABA-B9DA-FA1CD3EE776F

Q45099758-489A9AE4-3B82-4767-A3DD-A6B65D47F7B9

P2888

Q45099758-FE614831-83B7-42D4-BB5A-DD1BE66D5927

P304

Q45099758-036E6533-80AF-471F-99C5-AFDBFA59954B

P31

Q45099758-2CC0FA5A-8EA1-4738-BB51-6BB53C508AD1

P356

Q45099758-0A22961C-F931-4081-B22D-919EFD1E5B61

P433

Q45099758-15F22DD2-6316-4E7B-A9E8-C75A44C5BFEF

P478

Q45099758-A47B286A-7751-4D6A-88CF-2C49A54D9E19

P577

Q45099758-39DA870B-451D-414C-849E-E335627B0535

P6179

Q45099758-CDC4AE83-D945-46CF-93CE-6F7AA951E1A4

P698

Q45099758-7E6763A2-6AAF-4B83-826A-4C6F379983AF

P921

Q45099758-45030014-3050-4BD8-A9D5-80B353BC9F7F

P356

MODPATHOL.3800296

P1433

Modern Pathology

P1476

Reduced PTEN expression predic ...... arcinoma treated by tamoxifen.

@en

P2093

Andrew McFadden

http://www.w3.org/2001/XMLSchema#string

Emina Torlakovic

http://www.w3.org/2001/XMLSchema#string

Miķelis G Bickis

http://www.w3.org/2001/XMLSchema#string

Nael Shoman

http://www.w3.org/2001/XMLSchema#string

Rajni Chibbar

http://www.w3.org/2001/XMLSchema#string

Shannon Klassen

http://www.w3.org/2001/XMLSchema#string

P2860

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice

Regulation of Akt expression and phosphorylation by 17beta-estradiol in the rat uterus during estrous cycle

Nonparametric Estimation from Incomplete Observations

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Cellular survival: a play in three Akts

P2888

modpathol.3800296

P304

250-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.3800296

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028631783

http://www.w3.org/2001/XMLSchema#string

P698

15475931

http://www.w3.org/2001/XMLSchema#string

P921